This episode was originally aired on Wednesday 20 March 2024
This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion will cover the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.
Faculty: Bruno Sangro (Moderator), Umberto Cillo (Faculty) Helen Reeves (Faculty), María Reig (Faculty)
This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.
Related episodes:
- EASL Studio S5E13: Basics in decision-making for liver cancer treatment
- EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
- EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
- EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
- EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
- EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?
- EASL Studio S2E15: JHEP Live on the best animal model for HCC – Lost in translation?
The novel framework includes the concepts of multi-parametric and converse therapeutic hierarchy. |
BCLC staging and treatment strategy in 2022. |